Hope for lewy body dementia psychosis: new drug enters final testing phase
NCT ID NCT07095465
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests a drug called ACP-204 for treating psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a 52-week open-label extension, meaning all 126 participants will receive the drug. The main goal is to check for side effects over the long term. Participants must have completed a prior study of the same drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ACP-204 (a drug taken orally once daily)
- What this could lead to
- If successful, this could provide a long-term treatment option for psychosis in people with Lewy body dementia, helping manage symptoms.
- What could go wrong
- This is an extension study, not a new trial, and focuses on safety. It is still early to know if the drug works well long-term, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEWY BODY DEMENTIA PSYCHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ATP Clinical Research Inc.
Irvine, California, 92612, United States
-
Advanced Clinical Research Network, Corp
Miami, Florida, 33135, United States
-
Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry - Dr Ivo Natsov
Cherven Bryag, 5980, Bulgaria
-
Azienda Ospedaliera Univerrsitaria
Naples, Napoli, 80138, Italy
-
Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza, UOI Day Hospital di Neurologia
Roma, Roma, 185, Italy
-
CHU Strasbourg-Hopital Hautepierre
Strasbourg, 67000, France
-
CHU Tours- Hopital Bretonneau
Tours, Cedex 9, 37044, France
-
DCC "Sv. Vrach and Sv. Sv. Kuzma and Damyan", OOD
Sofia, 1408, Bulgaria
-
DCC Mladost M- Varna, OOD
Varna, 9000, Bulgaria
-
EvergreenHealth
Kirkland, Washington, 98034, United States
-
Fakultni Nemocnice u sv. Anny v Brne
Brno, 656 91, Czechia
-
Hawaii Pacific Neuroscience
Honolulu, Hawaii, 96817, United States
-
Health Synergy Clinical Research, LLC
West Palm Beach, Florida, 33407, United States
-
Homestead Associates in Research Inc
Miami, Florida, 33032, United States
-
Hopital Neurologique Bron
Bron, Rhone, 69677, France
-
Horizon Clinical Research Group
Cypress, Texas, 77429, United States
-
Humanity Clinical Research, Corp
Aventura, Florida, 33180, United States
-
Institute of Mental Health
Belgrade, 11000, Serbia
-
K2 Summit Research
Lady Lake, Florida, 32159, United States
-
MediClear Medical & Research Center, Inc.
Miami, Florida, 33165, United States
-
NEUROHK s.r.o. Poliklinika Chocen a.s.
Choceň, 56501, Czechia
-
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, 33486, United States
-
Parkinson's Disease and Movement Disorders Center of Boca Raton d/b/a Parkinson's Research Center of America-Long Island
Commack, New York, 11725, United States
-
R and H Clinical Research
Stafford, Texas, 77477, United States
-
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma, 74136, United States
-
The Ohio State University, Energy Advancement and Innovation Center
Columbus, Ohio, 43210, United States
-
University of Kansas Medical Center Research Institute Inc.
Kansas City, Kansas, 66160, United States
-
Università Campus Bio-Medico di Roma
Roma, Roma, 128, Italy
-
Vestra Clinics s.r.o
Rychnov nad Kněžnou, 51601, Czechia
-
Virginia Commonwealth University (a public institution of higher education)
Richmond, Virginia, 23219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.